Rapamycin vs. Autophagy: The Ultimate mTOR Inhibition Guide for Life Extension
Rapamycin is the most evidence-backed pharmacological longevity intervention available. This guide covers mTOR biology, weekly pulsed dosing rationale, the ITP mouse data, and what human trials actually show.
Evidence strength
Level 1b
Individual RCT
Peer-reviewed refs
4
Reading time
14 min
Key Takeaways
- Rapamycin extends lifespan in every model organism tested — yeast, worms, flies, and mice — representing four independent evolutionary lineages. The ITP found 9–14% median lifespan extension in mice started at age 20 months.
- Weekly pulsed dosing (3–6mg once weekly) achieves mTORC1 inhibition while preserving mTORC2 function — the critical distinction from continuous transplant-dose protocols.
- The Novartis everolimus trial showed 20% improved influenza vaccine response in elderly humans — the first direct evidence of immune rejuvenation in people.
- Rapamycin is a prescription medication requiring physician oversight, blood level monitoring, and quarterly lipid/glucose panels. Not a supplement.
Why mTOR Is the Master Ageing Switch
Every cell constantly monitors its environment: Are nutrients available? Is energy sufficient? Are growth factors present? The answers feed into a single integrating kinase: mTOR (Mechanistic Target of Rapamycin). When conditions are favourable, mTOR activates anabolic processes — protein synthesis, cell growth, and proliferation. When mTOR is active, autophagy is suppressed.
The problem with modern life is chronic mTOR hyperactivation. Abundant calories, constant protein intake, elevated insulin and IGF-1 — these signals keep mTOR permanently switched on. The cellular consequence: accumulated damage, suppressed autophagy, accelerated ageing.
Rapamycin inhibits mTOR Complex 1 (mTORC1) — specifically the complex that drives anabolic signalling and suppresses autophagy. By periodically inhibiting mTORC1, rapamycin forces the cell into a maintenance mode: cleaning up damaged proteins, removing dysfunctional mitochondria, and resetting cellular quality control.
The Lifespan Extension Evidence
The ITP (Interventions Testing Programme) is the gold standard for mammalian longevity research — testing compounds in genetically heterogeneous mice at three independent laboratories simultaneously to eliminate lab-specific artefacts.
Rapamycin has been tested multiple times with consistent results:
[1]| Study | Start Age | Median Lifespan Extension |
|---|---|---|
| ITP 2009 (Harrison) | 600 days (~60 human years) | 9% female, 14% male |
| ITP 2013 (Miller) | 270 days | 21% female, 22% male |
| ITP 2016 (various doses) | 270 days | Dose-dependent, up to 23% |
Critically, the 2009 study started rapamycin at 600 days of age — equivalent to approximately 60 years in humans. This establishes that rapamycin can extend lifespan even when started late. The intervention is not limited to early-life administration.
The Human Evidence — Immune Rejuvenation
The most important human rapamycin data comes from a 2014 Novartis trial using everolimus (a rapamycin analogue) in 218 adults aged 65+.
Participants received 6 weeks of everolimus before influenza vaccination. The results: approximately 20% improvement in vaccine antibody response compared to placebo — a direct measure of immune function. Additionally, the proportion of immunosenescent PD-1+ T-cells was reduced, suggesting partial reversal of T-cell ageing.
[4]A 2018 phase 2a follow-up randomised 264 elderly subjects to 6 weeks of a low-dose combination of two mTOR inhibitors (BEZ235 plus everolimus) that selectively inhibits TORC1, or placebo. The combination was safe, improved the response to influenza vaccination, up-regulated antiviral gene expression, and was associated with a significantly lower rate of reported infections over the following year.
[2]This is the first published evidence of pharmacological immune rejuvenation in humans.
Weekly Pulsed Dosing: The Critical Distinction
Transplant patients take 2–5mg rapamycin daily for immunosuppression. Longevity protocols use 3–10mg once weekly. This distinction is not trivial — it determines whether you achieve longevity benefits or create unnecessary risks.
The rationale rests on differential mTOR complex biology:
[3]mTORC1 (the longevity target) is acutely sensitive to rapamycin. Intermittent dosing inhibits mTORC1 and then allows recovery before the next dose.
mTORC2 (regulates glucose metabolism, cell survival) is much less sensitive to rapamycin and is not meaningfully inhibited by acute exposure, but chronic continuous dosing disrupts it — and many of rapamycin's side effects run through mTORC2. Intermittent pulsing aims to preserve mTORC2 function.
The evidence so far is from mice: an intermittent rapamycin schedule had minimal effects on glucose tolerance and a reduced impact on beta-cell function and the immune system compared with daily dosing. Weekly human protocols extrapolate from this logic rather than from head-to-head human trials.
Practical Protocol
Starting dose: 1mg/week for 4 weeks
Titration: 3mg/week for 8 weeks
Maintenance: 5mg/week (most longevity physicians use 5–6mg)
Advanced: Up to 10mg/week under close monitoring
Monitoring (non-negotiable):
- Trough rapamycin blood level: 24h post-dose, target 3–8 ng/ml
- Fasting lipids and glucose: quarterly
- CBC with differential: quarterly
- Pause 2–3 weeks before any surgery or during significant infection
Key interactions to avoid: Grapefruit juice, ketoconazole, clarithromycin (all increase rapamycin levels dramatically via CYP3A4 inhibition).
Rapamycin and Exercise
An important nuance: mTOR is also required for exercise-induced muscle protein synthesis. In theory, rapamycin on training days could blunt hypertrophic adaptations. Current evidence suggests scheduling rapamycin on a rest day and avoiding training within 24–48 hours post-dose minimises this concern. Most longevity physicians take rapamycin on Sunday if training Monday–Friday.
⚕ Rapamycin is a prescription immunosuppressant. This article is educational. Implement only under physician supervision with appropriate monitoring.
Related Substances
Scientific References
- [1]Harrison DE, et al.. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice — Nature (2009)Oxford 2bPMID 19587680
- [2]Mannick JB, Morris M, Hockey HP, et al.. TORC1 inhibition enhances immune function and reduces infections in the elderly — Science Translational Medicine (2018)Oxford 1bPMID 29997249
- [3]Arriola Apelo SI, Neuman JC, Baar EL, et al.. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system — Aging Cell (2016)Oxford 5PMID 26463117
- [4]Mannick JB, Del Giudice G, Lattanzi M, et al.. mTOR inhibition improves immune function in the elderly — Science Translational Medicine (2014)Oxford 1bPMID 25540326
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.